Introduction
Cardiac resynchronization therapy (CRT) improves symptoms and reduces morbidity and mortality. 1 -7 The 2007 ESC/EHRA Guidelines for Cardiac Pacing, 8 the 2008 ESC Heart Failure Guidelines, 9 and the 2008 ACC/AHA/HRS Guidelines for Device Therapy 10 provide class I A recommendation for CRT treatment with or without an implantable cardioverter defibrillator (ICD) function in patients with New York Heart Association (NYHA) functional class III and IV, QRS width ≥120 ms. and left ventricular ejection fraction (LVEF) ≤35% in order to improve symptoms and reduce mortality. More recent studies have explored the effect of CRT in patients with mild symptoms and markers of cardiac dyssynchrony most of whom were already indicated for an ICD, 5 -7 resulting in a focused ESC guideline update on device therapy. 11 Meanwhile, there has been a substantial increase in implantation rates for CRT across Europe, although with marked differences amongst countries. 12, 13 Surveys and registries differ from randomized controlled trials (RCTs) in several ways, and both approaches have their strengths and limitations. RCTs are designed to evaluate the response to interventions, but also measure outcomes, 14 by scientifically validated methods. However, they often exclude patients with co-morbidities and rely on statistical precision and consistency across subgroups. 15 Surveys capture data from a much more heterogeneous population and are closer to actual clinical practice. 16 -18 However, they are subject to selection bias and missing data, and only measure outcomes rather than the response to therapy. 14 We performed a survey to evaluate contemporary European practice related to CRT implantations with or without an ICD as a joint initiative of the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). The first publications, describing the patients and implant procedures, provided important information on clinical characteristics, diagnostic criteria, adverse events, in-hospital course, status at discharge, physician adherence to guideline recommendations, and the influence of the volume of implants at a centre. 19, 20 These reports show major differences between guidelines and clinical practice. Substantial numbers of patients had milder symptoms, narrow QRS width, and had a previous device (permanent pacemakers and ICDs). This publication reports the 1 year (9-15 months) follow-up results of patients included into this survey.
Methods Design
The rationale and design of the CRT Survey have been published previously. 21 All centres implanting CRT with or without an ICD were invited to participate. Centres were asked to enrol consecutive successful implantations performed between 1 November 2008 and 30 June 2009. The variables captured at 1 year follow-up included survival, hospitalization, patient global assessment (self-reported), NYHA functional class, electrocardiogram (ECG), key echocardiographic data, and device-related complications.
Participating countries and centres
A total of 141 centres from the following 13 ESC countries participated: Austria, Belgium, France, Germany, Ireland, Israel, Italy, The Netherlands, Norway, Spain, Sweden, Switzerland, and the UK. The number of patients from each is shown in Appendix 3.
Data collection
Data were collected using electronic case report forms (eCRFs). The contents for both index hospitalization and follow-up variables have been reported. 21 A follow-up assessment was planned 9 -15 months post-implantation. The window of 6 months was allowed in order to give enough time to capture data from routine device follow-ups. Two national co-ordinators, one each from the fields of heart failure and electrophysiology, were selected and given the responsibility of facilitating recruitment and follow-up in their respective countries (Appendix 1). Germany and Sweden have ongoing device registries in most of their centres which includes CRT which capture most of the information contained in the CRT Survey eCRF. With permission from both of the Steering Committees (Appendix 2), CRT follow-up data were merged into the CRT Survey database.
A central database was created at the data management centre, Institut für Herzinfarktforschung in Ludwigshafen an der Universität Heidelberg, Germany which also maintained and interrogated the database and performed analyses. A web site, www.crt-survey.org, supported by the ESC Web department provided all the relevant documents and permitted online data entry. Ethical approval and written informed consent were obtained according to the rules for clinical investigations in each participating country at the initiation of the study. 
Statistical methodology

Results
This survey enrolled 2438 patients during the 8 month inclusion period. One-year follow-up data (9-15 months), including vital status, were available for 2111 (87%) patients. Most patients received CRT with an ICD function (CRT-D) rather than CRT alone (CRT-P).
The characteristics of patients who did not have follow-up data were similar to those of the overall population. During follow-up, 207 (10%) patients died, 346 (16%) were hospitalized for cardiovascular causes, and 501 (24%) were hospitalized or died.
Mortality (Table 1) Patients who died were slightly older, were likely to be men, were more likely to have ischaemic heart disease, diabetes mellitus, chronic lung disease, and atrial fibrillation, had lower LVEF, were less likely to be prescribed beta-blockers and more likely to be prescribed diuretics, had worse NYHA functional class, and were more likely to be hospitalized for heart failure the previous year, as shown by unadjusted description of baseline characteristics in the table.
Patients with narrow QRS complex, left bundle branch block (LBBB), or paced ventricular rhythm had similar survival rates, but those with right bundle branch block (RBBB) had a worse outcome. Survivors were more likely to have received a CRT-D. Unadjusted Kaplan -Meier survival estimates suggested a better prognosis in patients who received a CRT-D than patients with a CRT-P (P , 0.0002, Figure 1A ).
Cardiovascular hospitalization and cardiovascular hospitalization or death ( Table 1) Women were hospitalized less frequently than men (25% vs. 20%, P , 0.05). Age, aetiology of disease, and prevalence of comorbidities, with the exception of atrial fibrillation, and the proportion of patients that received a CRT-D was similar in patients who did or did not have a CV hospitalization. QRS duration and morphology were similar amongst patients who were or were not hospitalized.
Patients who were hospitalized had a slightly lower LVEF, were more likely to be prescribed diuretics and aldosterone antagonists, had more severe symptoms, and were more likely to be hospitalized for heart failure in the year before implantation. The characteristics of patients who did or did not reach the composite outcome of cardiovascular hospitalization or death were similar to the pattern shown for survival.
Aetiology (Table 2, Figure 1)
Patients with ischaemic heart disease were older (71 vs. 68 years, P , 0.0001), more likely to be men, more likely to have a QRS duration ,130 ms (20% vs. 16%, P , 0.05), and less likely to have a QRS duration of between 130 and ,160 ms (31% vs. 36 %, P , 0.05) compared with patients who did not have ischaemic heart Follow-up results of the European CRT Survey disease. Patients with ischaemic heart disease had a somewhat worse outcome on both unadjusted and multivariable analyses.
Atrial fibrillation (Table 3, Figure 1)
Patients with atrial fibrillation were older (72 vs. 69 years, P , 0.0001), and more patients in this category had QRS durations , 130 ms (22% vs. 17%, P , 0.05), RBBB (9% vs. 6%, P , 0.01), and were allocated to a CRT-P rather than a CRT-D (39% vs. 29%, P , 0.0001). Patients with atrial fibrillation had a worse outcome on both unadjusted and multivariable analyses.
QRS durations
Except for a slightly higher mortality in patients with RBBB, outcomes were similar regardless of QRS morphology or duration or presence of paced ventricular rhythm. Patients with QRS ,130 ms were more likely to have ischaemic heart disease and be in atrial fibrillation.
Device type ( Table 4) CRT-D recipients were substantially younger (68 vs. 75 years, P , 0.0001), more likely to be women, and had significantly more previous ventricular fibrillation/sustained ventricular tachycardia (20% vs. 2%, P , 0.0001). The proportions of patients with different QRS morphology and durations were similar regardless of device type implanted.
Predictors of death and cardiovascular hospitalization ( Table 5 , and Figure 1 and 2)
Multivariable analyses were performed using the variables listed in Table 1 . These showed that NYHA functional class III -IV, atrial fibrillation, ischaemic aetiology, and allocation to device type CRT-P were independently associated with poorer survival.
Variables associated with re-hospitalization or for the combination of death or hospitalization were NYHA III -IV functional class and atrial fibrillation.
Upgraded patients vs. de novo implantations
A recent report from this database shows that outcomes in patients upgraded to CRT from permanent pacemakers and ICDs were similar to those who received de novo implantations. Clinical status ( Figure 3A and B)
Investigators reported a substantial improvement in NYHA functional class. At the time of implant, 1902 (78%) patients were in NYHA III -IV of whom 160 (8%) died. At follow-up 976 (50 %) patients were in NYHA III-IV. Of 536 (22%) patients who were in NYHA I -II at the time of implant, only 1% died. The proportion in NYHA I-II had risen to 995 (50%) patients at follow-up. For patients' self-reported assessment of their global condition, 81% felt much better/a little better, 16% reported no change, and 4% reported worsening.
Complications Table 6 reports device-related complications during the course of follow-up, with an overall rate of 10%. Lead displacement and phrenic nerve stimulation were the most common adverse events at 3%. Infection was reported in 1.6% of cases.
Discussion
This survey suggests that implanting a CRT-P or a CRT-D device is associated with broadly similar impact on symptoms and rates of hospitalization and survival as observed in landmark RCTs of patients with predominantly NYHA functional class III -IV heart failure, despite embracing a far broader range of patients that were also older and with more co-morbidity than in the landmark trials. Comparison of baseline characteristics and outcomes of the survey cohort with selected RCTs is provided in Table 7 . In CARE-HF, the 1-year mortality in patients assigned to CRT was 9.7% and 25% of patients had been hospitalized for a major cardiovascular event or died and by 18 months 62% were alive and in NYHA I-II. 23 A further analysis of CARE-HF that imputed the additional effect of adding an ICD function to CRT suggests that this would have provided an additional mortality benefit. 24 This survey suggests that implanting CRT devices into a broader population of patients who do not meet the inclusion criteria of the landmark trials is associated with a favourable outcome. However, this is no substitute for information from a RCT, and the data must be interpreted with caution. The population included important groups of patients poorly represented or excluded from RCTs, including women, very elderly patients, and those with prior device implantation, atrial fibrillation, and/or narrow QRS durations. 19 Women had a lower mortality than men despite being older and more likely to receive a CRT-P than a CRT-D. Lower mortality may reflect a lower prevalence of ischaemic disease in women, but randomized trials comparing ICD with CRT-D have suggested greater benefit in women. However, the effect of a CRT-P or a CRT-D on Follow-up results of the European CRT Survey mortality was similar in men and women in both CARE-HF and COMPANION. This survey cannot determine whether the better outcome in women reflects a better outcome to CRT or a better intrinsic prognosis amongst women. This survey suggests that age is not a strong determinant of 1-year outcome in patients who receive a CRT-P or CRT-D device, which is surprising since age is usually a strong predictor of survival in patients with heart failure. This could reflect a greater benefit of CRT in older patients, although randomized trials suggest a similar response in younger and older patients. Many more CRT-D than CRT-P devices are implanted in all ESC countries, although a substantial minority receive a CRT-P in some countries. The COMPANION study 3 and an imputed analysis of CARE-HF 25 suggest a modest additional survival benefit from a CRT-D. Patients who received a CRT-D device had a substantially lower mortality in both univariate and multivariate analysis, as has been reported in large patient series reported by others. 26 However, these findings should be interpreted cautiously since CRT-P recipients were older and had more atrial fibrillation. Moreover statistical analyses cannot correct for unrecorded confounders, hence the need for RCTs. The reasons for selecting a CRT-D in preference to a CRT-P device may account for much of the difference in outcome, although the inconclusive data from randomized trials support an additional therapeutic effect. Our survey included 544 patients (23 %) with atrial fibrillation. These patients were older, more likely to receive a CRT-P, and had higher morbidity and mortality. Clinical trials provide conflicting evidence regarding whether prevalent atrial fibrillation carries independent prognostic information after correction for differences for age and symptoms, although new-onset atrial fibrillation is associated with a sharp increase in mortality, suggesting that patients with chronic atrial fibrillation are a survivor subgroup. 27 The RAFT trial included 115 patients (13%) with atrial fibrillation or flutter. 7 No benefit of CRT-D compared with ICD was observed in this population. Information on the percentage of cumulative biventricular pacing, the extent of AV node ablation post-device implantation, or up-titration of medical treatment to ensure adequate pacing was not captured in this survey, which can potentially explain the observation of poorer outcome of patients with atrial fibrillation and the disparity with other observational data sets. 28 -33 Landmark RCTs comparing CRT-P and CRT-D against medical therapy included few patients with a QRS duration ,140 ms but did not identify a marked interaction between QRS duration and the effect of CRT on mortality. Patients with RBBB have a worse overall prognosis than those with LBBB, and may benefit less from CRT, although many patients who have additional left-sided fascicular blocks may still benefit. 2, 4, 34 More recently, trials comparing ICD and CRT-D have suggested that only patients with either QRS .150 ms or LBBB benefit from a CRT-D, 6, 7 although controversy surrounds which is more important. We found similar outcomes regardless of QRS duration. However, as patients with longer QRS duration would be expected to have a worse prognosis, the similar outcome could still be interpreted as a greater response in those with longer QRS duration. A substantial long-term trial to confirm or refute a benefit from implanting a CRT-P or CRT-D device compared with no device in patients regardless of QRS duration is required. Follow-up results of the European CRT Survey question. A large trial, Echo-CRT, is addressing the question of whether dyssynchrony measured by echocardiography can identify a group of patients with shorter QRS duration who benefit from CRT-D rather than ICD implantation, but will not answer the question of the impact of CRT compared with no device nor the impact of devices in patients with narrow QRS who do not have dyssynchrony.
Ischaemic heart disease predicts a worse outcome amongst patients with heart failure, and patients with ischeamic heart disease had a worse outcome in this survey. Randomized trials confirm that patients with ischaemic heart disease have a worse prognosis and less benefit from CRT in terms of ventricular remodelling 35 but, in terms of benefits on morbidity and mortality, the relative benefits in patients with and without ischaemic heart disease is similar 4, 6, 35 and therefore the absolute reduction in mortality may be somewhat greater in patients with ischeamic heart disease. The lack of insight into the mechanism of benefits of CRT is frustrating and may reflect the fact that the main mechanism of benefit varies from one patient to the next and from one time and situation to another. 36 Mitral regurgitation, prevention of tachy-and bradyarrythmias, ventricular remodelling, as well as atrioventricular and biventricular resynchronization may all play different roles at different times in this patient population. 14, 36 Like many successful interventions in heart failure, the lack of specificity is its secret of success.
Limitations
Surveys are important sources of information on how evidence acquired through RCTs, usually on highly selected patients managed according to detailed protocols, are adopted in clinical practice. However, surveys also have many limitations. Centre participation was voluntary and, among 800 invited implanting centres in the 13 participating ESC countries, 141 centres responded and recruited patients during the 8 months inclusion period. The 2009 EHRA white Book reports 30 000 annual CRT implantations in the participating countries (primary implants and replacements). 37 Although the importance of consecutive inclusion was emphasized, we cannot confirm that all patients were included consecutively, and there are several sources for potential investigator selection bias. Importantly, only successful implantations were entered into the database which selects the patient population, and could lead to an under-reporting of adverse experience in connection with implantation. The accuracy of the data has not been audited. NYHA functional class was investigator reported and the length of follow-up is short. There is a considerable variation in volume of participating centres 20 and the sample size for some of the eCRF variables due to incomplete data entry and lack of appropriate data fields in two device registries. However, the most important limitation of surveys is their inability to distinguish between outcome and response. 14 
Conclusions
This survey suggests that a group of patients representative of those encountered in routine clinical practice who received a CRT device considered their symptoms had improved compared wiht their pre-implant assessment. Overall survival was .90%. 
